By: IPP Bureau
Last updated : June 22, 2026 6:24 pm
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
Sun Pharmaceutical Industries Limited has announced the acquisition of Innovcare Lifesciences Private Limited, a Mumbai-based company engaged in the marketing, distribution and sale of pharmaceutical drugs, nutraceuticals and cosmeceutical products.
The transaction is aimed at strengthening Sun Pharma's product portfolio and expanding its presence in key healthcare segments.
Under the agreement, Sun Pharma, together with its subsidiaries and affiliates, will acquire 100% of the outstanding shares of Innovcare Lifesciences for a cash consideration of approximately Rs. 271.2 crore. The acquisition is expected to be completed on or before July 31, 2026.
According to the company's regulatory filing, the transaction does not qualify as a related-party transaction, and neither the promoter nor the promoter group has any interest in the target company.
Founded on July 21, 2014, Innovcare Lifesciences operates in the pharmaceuticals and healthcare sector, focusing on the marketing, distribution and sale of pharmaceutical drugs, nutraceutical products and cosmeceuticals across India.
The company reported revenue from operations of Rs. 94.06 crore in FY 2025-26, compared with Rs. 86.09 crore in FY 2024-25 and Rs. 80.93 crore in FY 2023-24, demonstrating consistent growth over the past three financial years.
Sun Pharma stated that the acquisition is a strategic investment designed to enhance its product offerings and reinforce its position in the healthcare market. No governmental or regulatory approvals are required for the completion of the transaction.
The acquisition aligns with Sun Pharma's broader strategy of strengthening its portfolio through targeted investments in complementary healthcare businesses and expanding its capabilities across pharmaceutical and consumer health categories.